Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in advanced biliary tract carcinoma
NCT02966821Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in biliary tract carcinoma (BTC), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Progression-free survival rate at 16 weeks. Started Jan 2017; status: completed.
02
Drugs
surufatinib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT02966821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966821.